APTIVUS
LOE ApproachingNDAORALSOLUTIONPriority Review
Approved
Jun 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
4/8 — Partial
Priority Review
APTIVUS by Boehringer Ingelheim is 12. First approved in 2008.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
APTIVUS (tipranavir) is an oral protease inhibitor antiretroviral used to treat HIV-1 infection in treatment-experienced patients with viral strains resistant to other protease inhibitors. It works by inhibiting HIV protease, preventing viral replication. The drug requires mandatory co-administration with ritonavir, a CYP3A inhibitor, to achieve therapeutic plasma concentrations.
$0.001BPart D
LOE ApproachingDeclining
Product is approaching loss of exclusivity with minimal market presence (577 Part D claims in 2023), signaling a small, contracting brand team.
Mechanism of Action
12.1 Mechanism of Action Tipranavir is an antiretroviral drug [ see ]. 12.2 Pharmacodynamics ECG Evaluation The effect of APTIVUS/ritonavir on the QTcF interval was measured in a study in which 81 healthy subjects received the following treatments twice daily for 2.5 days: APTIVUS/ritonavir (500…
Worked on APTIVUS at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.